A Pilot Trial of Oral Topotecan for the Treatment of Refractory Advanced Solid Neoplasms Expressing HIF-1a

NCT00117013 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

16

Enrollment

NIH

Sponsor class

Conditions

Neoplasms

Interventions

DRUG: Fluorine-19-Fluoroded Xyglucose
DRUG: Topotecan

Sponsor

National Cancer Institute (NCI)